BioCentury Launches the Third Decade of Future Leaders in the Biotech Industry

REDWOOD CITY, CA and NEW YORK, NY--(Marketwired - Mar 27, 2014) - BioCentury will convene the 21st Annual Future Leaders in the Biotech Industry in New York City on Friday, March 28th at 8 a.m. at the Millennium Broadway Hotel & Conference Center.

The event showcases a full slate of 57 biopharma companies hand-picked on the basis of investor validation, upcoming milestones, unpartnered assets and innovative science, informed by BioCentury's business intelligence platform.

Over 650 life science investment professionals and pharmaceutical business development and licensing executives have pre-registered for the event. Walk-up registration is available starting at 7:15 a.m. on Friday, March 28th on the 4th floor of the Millennium Broadway Conference Center, 133 West 44th Street.

The Future Leaders Class of 2014 has been doing its part to keep the biotech bull market running. The 29 public and 28 private companies have raised $6.7 billion in capital, including $3.1 billion since the beginning of 2013.

Public companies at Future Leaders are collectively up 43% this year, easily out-distancing the 16% jump in the BioCentury 100 Index as well as the 2% decline in the Dow Jones Industrial Average and 1% gain in the S&P 500. Over that same period, the aggregate market cap of the Future Leaders public companies has grown by $4.2 billion, from $9.9 billion to $14.1 billion.

This year's conference introduces a new Next Wave track of 15 early stage, privately held companies. The Next Wave track showcases platform plays and development companies advancing their assets to the clinic.

The Class of 2014 also features select IPO stories and public companies nearing key Phase II and III milestones in addition to international companies approaching value inflection points. Disease areas covered by the Class of 2014 include cancer, infectious disease, and neurological, cardiovascular and autoimmune disorders.

The Class of 2014 companies comprise a solid mix of innovative science and platform assets and provide ample partnering opportunities.

These Future Leaders have 11 marketed products, 15 products in Phase III/Registration, 53 products in Phase II development, 56 products in Phase I and at least 88 products in preclinical development. More than 100 products are currently unpartnered.

"While we know that bull markets can't last forever, they typically don't end when companies have strong balance sheets and upcoming transformational milestones," said BioCentury Publisher Eric Pierce. "The Future Leaders Class of 2014 is aiming to show how they can create more value for investors going forward."